Q&A With Sutro's William Newell

Sutro Biopharma’s most visible advocate is CEO Bill Newell, 58, who has led the company since January 2009 – almost an eternity in the unpredictable culture of the start-up enterprise. Newell has a background in legal, business development and finance. This has helped ensure Sutro is well financed and prominently positioned for the external partnerships that will build a market for the company’s complex proprietary technology and boost the accuracy and potency of drug delivery in destroying cancerous tumor cells, with minimum impact on patient well-being. In the interview below, Newell discusses the progress of Sutro’s commercialization programs on ADCs as well as lessons on leading a small biotech in a crowded competitive field of big pharma players.